Form 4: UnitedHealth Group Director Paul R. Garcia Reports Changes in Beneficial Ownership

Director Paul R. Garcia reports acquisition of UnitedHealth Group common stock and deferred stock units as part of regular quarterly compensation.

Summary

• On October 1, 2024, Paul R. Garcia, a director of UnitedHealth Group, acquired 97 deferred stock units and 54 shares of common stock as part of regular quarterly compensation for his service on the Board.
• The deferred stock units are immediately vested but must be retained until Garcia's completion of service on the Board.
• Following these transactions, Garcia directly owns 2,062 shares of common stock, and 2,116 shares of common stock.
• Garcia also indirectly owns 2,146 shares via a revocable trust, 45 shares via Trust 2, and 55 shares via Trust 3.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing detailing stock transactions related to director compensation, indicating a neutral to slightly positive sentiment due to ongoing director investment.

Positives

• The acquisition of stock and deferred stock units reflects ongoing compensation for Garcia's role as a director.
• The vesting of deferred stock units aligns Garcia's interests with the long-term performance of UnitedHealth Group.

Industry Context

This filing is a routine disclosure related to director compensation and stock ownership, common in publicly traded companies like UnitedHealth Group.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock options, and restricted stock units.
• The specifics of these packages vary widely based on company size, industry, and individual contributions.
• Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also regularly disclose similar transactions by their directors and officers.
• These disclosures are mandated by SEC regulations to ensure transparency and prevent insider trading.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• They provide transparency regarding director compensation and alignment with shareholder interests.

Key Dates